165 related articles for article (PubMed ID: 28282547)
1. Study of association between interleukin-17 and interferon-gamma and recombinant human erythropoietin dose in patients undergoing peritoneal dialysis.
de Oliveira WV; de Figueiredo RC; de Paula AS; Turani SD; Velloso MSS; Pinheiro MB; Gomes KB; Marinho MAS; Pinto SWL; Rios DRA
Cytokine; 2017 Aug; 96():24-29. PubMed ID: 28282547
[TBL] [Abstract][Full Text] [Related]
2. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.
Sitter T; Bergner A; Schiffl H
Nephrol Dial Transplant; 2000 Aug; 15(8):1207-11. PubMed ID: 10910446
[TBL] [Abstract][Full Text] [Related]
3. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis.
Sharples EJ; Varagunam M; Sinnott PJ; McCloskey DJ; Raftery MJ; Yaqoob MM
Perit Dial Int; 2006; 26(1):64-8. PubMed ID: 16538877
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines.
Macdougall IC; Cooper AC
Nephrol Dial Transplant; 2002; 17 Suppl 11():39-43. PubMed ID: 12386257
[TBL] [Abstract][Full Text] [Related]
6. Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia.
Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
Biochimie; 2016 Jun; 125():150-62. PubMed ID: 27039028
[TBL] [Abstract][Full Text] [Related]
7. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.
Matsuhashi N; Yoshioka T
Nephron; 2002; 92(3):601-4. PubMed ID: 12372943
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
9. High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients.
Kato A; Odamaki M; Takita T; Furuhashi M; Maruyama Y; Hishida A
Nephrol Dial Transplant; 2001 Sep; 16(9):1838-44. PubMed ID: 11522867
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin and sexual dysfunction.
Lawrence IG; Price DE; Howlett TA; Harris KP; Feehally J; Walls J
Nephrol Dial Transplant; 1997 Apr; 12(4):741-7. PubMed ID: 9141005
[TBL] [Abstract][Full Text] [Related]
11. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
12. Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients.
Aguilera A; Bajo MA; Díez JJ; Ruiz-Caravaca ML; Vicenta Cuesta M; Alvarez V; Codoceo R; Selgas R
Adv Perit Dial; 2002; 18():200-5. PubMed ID: 12402619
[TBL] [Abstract][Full Text] [Related]
13. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
[TBL] [Abstract][Full Text] [Related]
14. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
15. High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients.
Pavese I; Satta F; Todi F; Di Palma M; Piergrossi P; Migliore A; Piselli P; Borghesi R; Mancino G; Brunetti E; Alimonti A
Ann Oncol; 2010 Jul; 21(7):1523-1528. PubMed ID: 20032122
[TBL] [Abstract][Full Text] [Related]
16. Association between erythropoietin requirements and antihypertensive agents.
Yano S; Suzuki K; Iwamoto M; Urushidani Y; Yokogi H; Kusakari M; Aoki A; Sumi M; Kitamura K; Sanematsu H; Gohbara M; Imamura S; Sugimoto T
Nephron Clin Pract; 2008; 109(1):c33-9. PubMed ID: 18506108
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the influenza-like symptoms associated with recombinant human erythropoietin therapy.
Takemasa A; Yorioka N; Yamakido M
J Int Med Res; 1997; 25(3):127-34. PubMed ID: 9178144
[TBL] [Abstract][Full Text] [Related]
18. Anemia of chronic renal failure: treatment with erythropoietin.
Navarro M; Alonso A; Avilla JM; Espinosa L
Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
[TBL] [Abstract][Full Text] [Related]
19. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress.
Stenvinkel P; Bárány P
Nephrol Dial Transplant; 2002; 17 Suppl 5():32-7. PubMed ID: 12091605
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin and the anemia of chronic diseases.
De Marchi S; Pirisi M; Ferraccioli GF
Clin Exp Rheumatol; 1993; 11(4):429-44. PubMed ID: 8403591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
